https://thymidinechemical.com/....prospects-associated
Following a 12-week intervention, the key outcome measure was the change from baseline in the frequency of 24-hour cough. A total of 310 volunteers were randomly allocated to one of four treatment arms: eliapixant 25 mg twice daily (n=75), 75 mg twice daily (n=78), 150 mg twice daily (n=8, or placebo (n=77). A statistically significant dose-response effect of eliapixant was observed for the primary endpoint, which held true across all dose
Like
Comment
Share
